{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T09:45:14Z","timestamp":1785059114307,"version":"3.55.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"DOI":"10.7759\/cureus.107028","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:20:57Z","timestamp":1776176457000},"source":"Crossref","is-referenced-by-count":2,"title":["Severe Euglycemic Ketoacidosis Secondary to Tirzepatide Use for Weight Loss"],"prefix":"10.7759","author":[{"given":"Alhassan","family":"Hassan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.12890\/2024_004357","article-title":"Tirzepatide-induced ketoacidosis in non-diabetic patients","volume":"11","author":"Iqbal PM","year":"2024","unstructured":"Iqbal PM, Maadarani OS, Bitar ZI. Tirzepatide-induced ketoacidosis in non-diabetic patients. Eur J Case Rep Intern Med. 2024, 11:004357. 10.12890\/2024_004357","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.946133","article-title":"Exploring hypoglycemic ketoacidosis in nondiabetic patients on tirzepatide: is starvation the culprit?","volume":"25","author":"Bitar Z","year":"2024","unstructured":"Bitar Z, Abdelraouf HM, Maig RA, Maadarani O, Bitar ZZ, Dashti H. Exploring hypoglycemic ketoacidosis in nondiabetic patients on tirzepatide: is starvation the culprit?. Am J Case Rep. 2024, 25:e946133. 10.12659\/AJCR.946133","journal-title":"Am J Case Rep"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2174\/1573399812666160421121307","article-title":"Euglycemic diabetic ketoacidosis: a review","volume":"13","author":"Modi A","year":"2017","unstructured":"Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev. 2017, 13:315-21. 10.2174\/1573399812666160421121307","journal-title":"Curr Diabetes Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v12.i5.514","article-title":"Euglycemic diabetic ketoacidosis: A missed diagnosis","volume":"12","author":"Nasa P","year":"2021","unstructured":"Nasa P, Chaudhary S, Shrivastava PK, Singh A. Euglycemic diabetic ketoacidosis: A missed diagnosis. World J Diabetes. 2021, 12:514-23. 10.4239\/wjd.v12.i5.514","journal-title":"World J Diabetes"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-17-0081","article-title":"Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma","volume":"2017","author":"Rawla P","year":"2017","unstructured":"Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017, 2017:10.1530\/EDM-17-0081","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12465","article-title":"Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity","volume":"18","author":"Burcelin R","year":"2017","unstructured":"Burcelin R, Gourdy P. Harnessing glucagon-like peptide-1 receptor agonists for the pharmacological treatment of overweight and obesity. Obes Rev. 2017, 18:86-98. 10.1111\/obr.12465","journal-title":"Obes Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck MA","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021, 46:101102. 10.1016\/j.molmet.2020.101102","journal-title":"Mol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge K","year":"2017","unstructured":"Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017, 19:336-47. 10.1111\/dom.12824","journal-title":"Diabetes Obes Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2143\/ACB.66.5.2062583","article-title":"Metformin and lactic acidosis","volume":"66","author":"Scheen AJ","year":"2011","unstructured":"Scheen AJ. Metformin and lactic acidosis. Acta Clin Belg. 2011, 66:329-31. 10.2143\/ACB.66.5.2062583","journal-title":"Acta Clin Belg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.1803","article-title":"Neuropsychiatric adverse events associated with glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database","volume":"68","author":"Lu W","year":"2025","unstructured":"Lu W, Wang S, Tang H, Yuan T, Zuo W, Liu Y. Neuropsychiatric adverse events associated with glucagon-like peptide-1 receptor agonists: a pharmacovigilance analysis of the FDA Adverse Event Reporting System database. Eur Psychiatry. 2025, 68:e20. 10.1192\/j.eurpsy.2024.1803","journal-title":"Eur Psychiatry"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.83187","article-title":"Euglycemic ketoacidosis in a non-diabetic patient after tirzepatide use: a cautionary tale","volume":"17","author":"Singh R","year":"2025","unstructured":"Singh R. Euglycemic ketoacidosis in a non-diabetic patient after tirzepatide use: a cautionary tale. Cureus. 2025, 17:e83187. 10.7759\/cureus.83187","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/480271-severe-euglycemic-ketoacidosis-secondary-to-tirzepatide-use-for-weight-loss","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:20:57Z","timestamp":1776176457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/480271-severe-euglycemic-ketoacidosis-secondary-to-tirzepatide-use-for-weight-loss"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.107028","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,14]]}}}